Skip to main content

Big Pharma missing Link In Canadas Emerging Marijuana Industry

The entrance of multinational pharmaceutical companies into Canada’s cannabis sector will mark one of the next major themes in the industry, analysts told Marijuana Business Daily.

Such eventual moves by Big Pharma will provide even more credibility to a sector that has already seen the entrance of alcohol and tobacco giants.

“The missing link is in the pharmaceutical part of the equation,” David Kideckel, director of Altacorp Capital’s life sciences division, said in an interview with MJBizDaily.

“That’s going to be an ongoing theme for 2019 – M&A and how these so-called legacy industries move in.”

Thus far, there have been no major direct investments from pharmaceutical companies into medical cannabis licensed producers.

But a recent Altacorp report said that drought could “come to a halt” once the U.S. legalizes cannabis at a federal level.

“As far as making really big deals, I don’t think you’re going to see anything substantial in terms of an equity stake until companies feel more comfortable with where U.S. federal policy is going,” Kideckel said.

Kideckel recently initiated coverage of Valens GroWorks, Auxly Cannabis Group and GW Pharmaceuticals.

In the meantime, the cannabis sector can expect to see more partnerships such as Tilray’s deal with Quebec-based pharmaceutical firm Sandoz AG and CannTrust’s deal with Ontario-based Apotex.

“Those kinds of deals can be a prelude for pharma to get its feet wet in the cannabis industry,” Kideckel said. “Distribution agreements could unfold.”

Who are the likeliest targets for Big Pharma?

“Companies involved in the cannabis space with competitive differentiation surrounding their R&D capacity, clinical trials program or commercialization efforts would be a prime candidate for Big Pharma to engage in talks with,” Kideckel noted.

Alcohol and tobacco are stepping stones to “the really big brands that will ultimately arrive here,” said Khurram Malik, a partner with Toronto-based financial advisory firm Jacob Capital Management.

“The really big ones for me are consumer packaged goods,” Malik added. “When you get the Nestles and Coca-Colas of the world coming in, that’s when it will get interesting.”

Legacy companies are waiting to see who can successfully build brands in the THC and CBD industries before pulling the trigger on major M&As.

Coca-Cola said in September it was eyeing the development of CBD-infused beverages, and Bloomberg reported the beverage giant was in talks with Aurora Cannabis to develop such a line.

“As far as CBD goes, until cannabis companies have a large enough consumer recreational brand presence, they’re not going to sweep in,” Malik said.

“They don’t want to create a brand, they want to buy one and take it to the next level.”

He said nondiversified beverage or tobacco companies might be more inclined to get involved earlier to help develop products and brands to stem potential losses from cannabis, but diversified consumer packaged goods companies are in no such rush.

Those organizations don’t feel the same competitive tension to get involved in cannabis, he said.

“They’ll wait until someone gets big enough and make it worth their while.”

Matt Lamers can be reached at [email protected]

To sign up for our weekly international marijuana business newsletter, click here.

Original Article Source: https://mjbizdaily.com/big-pharma-missing-link-in-canadas-emerging-cannabis-industry/

Comments

Post a Comment

Popular posts from this blog

New York City Adds More Exceptions To Pre-Employment Marijuana Testing Ban

An ambitious campaign to decriminalize psychedelics in Washington, D.C., is one step closer to placing their measure on the November ballot with the formal submission of tens of thousands of voter signatures. Organizers have been scrambling for weeks to collect enough signatures from D.C. voters by Monday’s deadline amid historically difficult circumstances: a global pandemic, months of stay-at-home orders and protests over racism and police violence that filled the streets of the nation’s capital. But with the help of innovative signature-gathering techniques and allies flown in from across the country, advocates said they had successfully submitted upwards of 35,000 signatures—more than enough to qualify the initiative. If approved by voters, Initiative 81 would make enforcement of laws against plant- and fungus-based psychedelics among the “lowest law enforcement priorities” for the Metropolitan Police Department. It would not, however, legalize or reduce penalties for the subs
Post a Comment
Read more

Charlotte Figi The Girl Who Inspired A CBD Movement Has Died At Age 13

Charlotte had recently been hospitalized due to pneumonia, breathing problems and seizures. She was treated as a likely case of Covid-19, her mother, Paige Figi, said Wednesday, although she tested negative for the virus. “Charlotte is no longer suffering. She is seizure-free forever,” a family friend wrote on Paige Figi’s Facebook page, announcing Charlotte’s death. “Thank you so much for all of your love.” Charlotte became a symbol of the possibilities of CBD after CNN Chief Medical Correspondent Dr. Sanjay Gupta told her story in the documentary “Weed.” In the film, Charlotte was shown to be a playful child who was overcome by horrific seizures, which were quelled with Charlotte’s Web, a marijuana strain named in her honor. Charlotte had Dravet syndrome, a rare form of epilepsy which was not controlled by medication. The Stanley brothers, marijuana growers in Colorado, were crossbreeding a strain of marijuana high in CBD and low in THC, its psychoactive ingredient. After Charlo
Post a Comment
Read more

Virginia CBD Program Criticized As Multistate Medical Cannabis Operators Gain Edge

Seven companies are challenging a CBD licensing process in Virginia that resulted in multistate medical marijuana operators getting a majority of available licenses. The appeals called the process “wildly prejudicial.” Out of 51 applicants for five vertically integrated CBD and THC-A licenses, multistate operators received three, a situation that spurred the appeals, The Virginian-Pilot reported. Applicants filing the appeals complained the closed-meeting review process lacked fairness and transparency. One consultant to an applicant said the selections felt “predetermined.” The Virginia Board of Pharmacy reportedly sent information to the applicants in December explaining its selections, but some applicants weren’t satisfied. A board spokeswoman wrote in an email to the Pilot that the board “does not comment on pending litigation.” The five winning applicants , called “pharmaceutical processors,” have a year from winning the licenses to become operational. The multistate
Post a Comment
Read more